Immatics (IMTX) Return on Capital Employed (2020 - 2025)
Immatics (IMTX) reported Return on Capital Employed of 45.62% for Q4 2025, down 4714.0% on a YoY basis from 0.99% in Q4 2024, and down 43.57% sequentially from 31.78% in Q3 2025.
Immatics (IMTX) Return on Capital Employed (2020 - 2025) Analysis & Trends
Immatics (IMTX) has 6 years of Return on Capital Employed data on file, last reported at 45.62% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 4714.0% year-over-year to 45.62%; the trailing twelve-month figure through Dec 2025 stood at 45.62% (down 4714.0% YoY), and the FY2025 full-year result was 31.84%, down 2462.0% from the prior year.
- Return on Capital Employed slipped to 45.62% in Q4 2025, from 31.78% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 18.25% in Q4 2022 to a low of 180.45% in Q2 2021.
- A 5-year average of 37.4% and a median of 22.52% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 19285 bps in 2022 and sank 5162 bps in 2023, its largest moves.
- Tracing IMTX's Return on Capital Employed over 5 years: stood at 104.83% in 2021, then jumped by 117 bps to 18.25% in 2022, then slumped by 283 bps to 33.37% in 2023, then surged by 105 bps to 1.51% in 2024, then sank by 3118 bps to 45.62% in 2025.
- Business Quant data shows IMTX's Return on Capital Employed at 45.62% in Q4 2025, 31.78% in Q3 2025, and 22.24% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - | -45.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -45.62% |
| Sep 30, 2025 | -31.78% |
| Jun 30, 2025 | -22.24% |
| Mar 31, 2025 | -6.93% |
| Dec 31, 2024 | 1.51% |
| Sep 30, 2024 | -13.61% |
| Jun 30, 2024 | -15.80% |
| Mar 31, 2024 | -19.79% |
| Dec 31, 2023 | -33.37% |
| Sep 30, 2023 | -28.10% |
| Jun 30, 2023 | -28.52% |
| Mar 31, 2023 | -22.79% |
| Dec 31, 2022 | 18.25% |
| Sep 30, 2022 | 16.08% |
| Jun 30, 2022 | 12.39% |
| Mar 31, 2022 | 6.65% |
| Dec 31, 2021 | -104.83% |
| Sep 30, 2021 | -101.23% |
| Jun 30, 2021 | -180.45% |
| Mar 31, 2021 | -147.91% |